30 October 2021 | News
The company aims to develop a cutting-edge and affordable treatment option for COVID-19 and neutralise the disease in minimum treatment duration
Optimus Group has announced the successful completion of the much-awaited Molnupiravir Oral Capsule Phase 3 Clinical Trial. The pharmaceutical company was the first to file for Phase 3 Clinical Trial of Molnupiravir with the Central Licensing Authority. The Clinical Trial partner of Optimus, JSS Research was tasked with the execution of the trial at the grass-root level.
With 29 study sites across India roughly covering 96 per cent of the nation’s demographic capital, the trial not only aims to prove the superiority of Molnupiravir over the standard treatment options but also prove the drug’s efficacy across India’s gene pool diversity.
Speaking on the development, Dr D Srinivas Reddy, CMD, Optimus Pharma said, “With an indigenously developed formulation, Optimus strives to establish its belief in the Make in India initiative of the Government of India. We aim to develop a cutting-edge and affordable treatment option for COVID-19 and neutralise the disease in minimum treatment duration. We are fully committed to supporting our business partners across various regions of the world who are counting on us for the supply of Molnupiravir.”